The abstract is read at the publisher; the summary is JClub's.
In high-risk stage III colon adenocarcinoma (pT4 and/or pN2) after R0 resection, adjuvant mFOLFIRINOX did not improve 3-year disease-free survival versus mFOLFOX6 (65.6% vs 66.3%).
- Why it matters: Patients with pT4 and/or pN2 stage III disease remain at high recurrence risk despite oxaliplatin-based adjuvant chemotherapy, leaving uncertainty about whether triplet intensification helps.
- What they did: In an international open-label randomized phase III trial, 795 patients received mFOLFIRINOX or mFOLFOX6 every 2 weeks for 12 cycles, with 3-year DFS as the primary endpoint.
- The result: With median follow-up of 55 months, DFS was similar (HR 1.07, 95% CI 0.84-1.36; P = 0.61), and toxicity differed without a DFS benefit, so intensification is not supported.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.